This is a StreetInsider.com Premium Only Page

Amarin Corp. (AMRN) – StreetInsider.com Reports

Apr 8, 2024 08:01 AM Amarin Corp. (AMRN) Highlights Key Data Providing Mechanistic Insights into Eicosapentaenoic Acid (EPA) at ACC.24

Apr 3, 2024 08:00 AM Amarin Corp. (AMRN) Issues Update on VAZKEPA Intellectual Property Portfolio in Europe

Feb 29, 2024 07:10 AM Amarin Corp. (AMRN) Tops Q4 EPS by 3c, offers outlook

Jan 22, 2024 07:30 AM Amarin Corp. (AMRN) CEO Issue Letter to Shareholders

Jan 10, 2024 07:02 AM Amarin Corp. (AMRN) Provides Preliminary Fourth Quarter 2023 Selected Financials and Outlines Key Priorities For 2024

Dec 4, 2023 05:32 PM After-hours movers: GitLab surges on earnings, EyePoint adds to intra-day gains

Dec 4, 2023 04:24 PM Sarissa Capital Believes Amarin (AMRN) Stock Is Meaningfully Undervalued, Increases Its Ownership

Dec 4, 2023 08:04 AM Catalyst Pharmaceuticals (CPRX) Announces Appointment of Michael W. Kalb as Chief Financial Officer and Other Executive Promotions

Nov 20, 2023 03:59 AM JPMorgan Reinstates Amarin Corporation (AMRN) at Underweight

Nov 13, 2023 05:33 AM Amarin Corp. (AMRN) Reports New REDUCE-IT Data Showing VASCEPA Associated with 29 Percent Relative Risk Reduction Compared with Placebo

Nov 1, 2023 07:09 AM Amarin Corp. (AMRN) Reports In-Line Q3 EPS

Oct 25, 2023 04:46 AM Jefferies Downgrades Amarin Corporation (AMRN) to Hold

Aug 17, 2023 10:07 AM Amarin's (AMRN) new CEO buys $300k in stock as promised

Aug 9, 2023 04:06 PM Amarin (AMRN) Provides Pricing & Reimbursement Updates for VAZKEPA in The Netherlands and Italy

Aug 8, 2023 07:02 AM Amarin (AMRN) And Neopharm Enter Exclusive Commercialization Agreement for VAZKEPA in Israel

Aug 7, 2023 07:01 AM Amarin Corp. (AMRN) VAZKEPA accepted by the Scottish Medicines Consortium

Aug 2, 2023 08:36 AM Amarin Corp. (AMRN) Files $100M Mixed Shelf

Aug 2, 2023 07:12 AM Amarin Corp. (AMRN) Tops Q2 EPS by 5c

Jul 26, 2023 08:01 AM Amarin Corp. (AMRN) Latest Research Evaluating Clinical Benefits of VASCEPA/VAZKEPA to be Presented at ESC Congress

Jul 25, 2023 04:06 PM Amarin Corp. (AMRN) Receives Positive Recommendation from Spanish Drug Pricing Committee for National Reimbursement of VAZKEPA

Jul 19, 2023 09:36 AM Amarin Corporation (AMRN) PT Lowered to $1.25 at Northland Capital Markets

Jul 19, 2023 07:06 AM Amarin (AMRN) PT Lowered to $1 at Goldman Sachs, "stock to remain range bound until execution improves"

Jul 18, 2023 04:16 PM Amarin (AMRN) Appoints Patrick Holt as President and CEO

Jul 18, 2023 04:16 PM Amarin Corp. (AMRN) Announces Organizational Restructuring

Jun 21, 2023 09:01 AM Amarin (AMRN) Announces Vascepa Approved in Saudi Arabia to Reduce Cardiovascular Risk

Jun 1, 2023 06:00 AM Amarin's (AMRN) Partner EddingPharm Receives Regulatory Approval for Vascepa in China

May 3, 2023 07:01 AM Amarin Corp. (AMRN) Tops Q1 EPS by 5c

Apr 17, 2023 07:01 AM Amarin Corp. (AMRN) Appoints Aaron Berg Interim CEO

Apr 4, 2023 08:05 AM Amarin Corp. (AMRN) Announces VAZKEPA Approved by Israel's Ministry of Health

Mar 31, 2023 09:06 AM Amarin Corp. (AMRN) President and CEO Karim Mikhail to Resign

Mar 16, 2023 08:02 AM Amarin Corp. (AMRN) Says Reconstituted Board Ready for the Challenge of Unlocking True Potential of VASCEPA®/VAZKEPA

Mar 6, 2023 04:07 PM Amarin Corp. (AMRN) Announces Board Departures

Mar 6, 2023 08:09 AM Amarin (AMRN) Highlights New Evidence of Therapeutic Value of EPA in Reducing Cardiovascular Events in At-Risk Patients Presented at ACC.23/WCC

Mar 1, 2023 07:07 AM Amarin Corp. (AMRN) Tops Q4 EPS by 3c

Feb 28, 2023 10:39 AM Sarissa Capital Wins Proxy Contest Against Amarin (AMRN) by Huge Landslide

Feb 28, 2023 10:38 AM Amarin Corp. (AMRN) says shareholders have voted to elect all seven of Sarissa’s nominees

Feb 28, 2023 08:01 AM Amarin Corp. (AMRN) and CSL Seqirus Announce Exclusive License and Distribution Agreement to Commercialize VAZKEPA in Australia and New Zealand

Feb 27, 2023 04:29 PM Amarin (AMRN) Comments on Sarissa’s "Latest Misstatements"

Feb 27, 2023 08:01 AM Amarin Corp. (AMRN) to Present New Data Evaluating VASCEPA/VAZKEPA

Feb 17, 2023 09:04 AM Amarin Corp. (AMRN) Urges Shareholders to Vote "Against" Sarissa's Harmful Proposals at Upcoming General Meeting

Feb 17, 2023 07:31 AM Sarissa Capital Urges Amarin (AMRN) Shareholders to Vote for Change and Remake Amarin for Shareholders

Feb 16, 2023 04:06 PM Sarissa Capital Response to Amarin (AMRN)

Feb 7, 2023 04:36 PM Sarissa Capital Highlights Amarin’s (AMRN) Inaccurate and Misleading Statements

Feb 2, 2023 04:31 PM Amarin Corp. (AMRN) Mails Letter to Shareholders Highlighting New Board and Superior Leadership

Jan 31, 2023 08:27 AM Amarin Corp. (AMRN) Files Definitive Proxy Materials and Mails Letter to Shareholders

Jan 27, 2023 08:46 AM Amarin Corp. (AMRN) Announces VAZKEPA Approved By Medsafe In New Zealand

Jan 10, 2023 01:42 PM Sarissa Capital submits notice on Amarin Corp. (AMRN) for special meeting to add director and remove Chairman

Jan 10, 2023 07:17 AM Amarin Corp. (AMRN) Prelim. Q4 Revenue Tops Consensus

Jan 10, 2023 07:02 AM Amarin (AMRN) Appoints Murray W. Stewart to its Board

Jan 6, 2023 09:16 AM Jefferies Upgrades Amarin Corporation (AMRN) to Buy